Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women

por Lu, Yen-Shen, Wong, Andrea, Kim, Hee-Jeong
Publicado 2021

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

por Chang, Dwan-Ying, Ma, Wei-Li, Lu, Yen-Shen
Publicado 2021

IκB kinases increase Myc protein stability and enhance progression of breast cancer cells

por Yeh, Pei-Yen, Lu, Yen-Shen, Ou, Da-Liang, Cheng, Ann-Lii
Publicado 2011

Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women

por Chuang, Shu‐Chun, Lin, Ching‐Hung, Lu, Yen‐Shen, Hsiung, Chao Agnes
Publicado 2019

Associations between Medical Conditions and Breast Cancer Risk in Asians: A Nationwide Population-Based Study in Taiwan

por Chuang, Shu-Chun, Wu, Guo-Jie, Lu, Yen-Shen, Lin, Ching-Hung, Hsiung, Chao Agnes
Publicado 2015

An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer

por Lu, Yen-Shen, Yeo, Winnie, Yap, Yoon-Sim, Park, Yeon Hee, Tamura, Kenji, Li, Huiping, Cheng, Rebecca
Publicado 2021

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

por Vogel, Charles, Chan, Arlene, Gril, Brunilde, Kim, Sung-Bae, Kurebayashi, Junichi, Liu, Li, Lu, Yen-Shen, Moon, Hanlim
Publicado 2010

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

por Chen, I-Chun, Hu, Fu-Chang, Lin, Ching-Hung, Huang, Shu-Min, Chang, Dwan-Ying, Cheng, Ann-Lii, Lu, Yen-Shen
Publicado 2021

Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs

por Hata, Tomomi, Nakamura, Kenichi, Yonemori, Kan, Noguchi, Emi, Watanabe, Makiko, Sohn, Joohyuk, Lu, Yen‐Shen, Yap, Yoon‐Sim, Tamura, Kenji, Fujiwara, Yasuhiro
Publicado 2021

The Prevalence and Assessment of ErbB2-Positive Breast Cancer in Asia: A Literature Survey

por Tan, Yew Oo, Han, Sehwan, Lu, Yen-Shen, Yip, Cheng-Har, Sunpaweravong, Patrapim, Jeong, Joon, Caguioa, Priscilla B, Aggarwal, Shyam, Yeoh, Ee Min, Moon, Hanlim
Publicado 2010

Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival

por Chen, Tom Wei-Wu, Jan, I-Shiow, Chang, Dwang-Ying, Lin, Ching-Hung, Chen, I-Chun, Chen, Ho-Min, Cheng, Ann-Lii, Lu, Yen-Shen
Publicado 2020

Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy

por Kuo, Yu-Hsuan, Lin, Ching-Hung, Shau, Wen-Yi, Chen, Te-Jung, Yang, Shih-Hung, Huang, Shu-Min, Hsu, Chun, Lu, Yen-Shen, Cheng, Ann-Lii
Publicado 2012

A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

por Wu, Pei-Fang, Lin, Ching-Hung, Kuo, Ching-Hua, Chen, Wei-Wu, Yeh, Dah-Cherng, Liao, Hsiao-Wei, Huang, Shu-Min, Cheng, Ann-Lii, Lu, Yen-Shen
Publicado 2015

Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

por Kuo, Chun-Ting, Chen, Chen-Lin, Li, Chih-Chi, Huang, Guan-Syuan, Ma, Wei-Yuan, Hsu, Wei-Fan, Lin, Ching-Hung, Lu, Yen-Shen, Wo, Andrew M.
Publicado 2019

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

por Kuo, Chun-Ting, Chen, Chen-Lin, Li, Chih-Chi, Huang, Guan-Syuan, Ma, Wei-Yuan, Hsu, Wei-Fan, Lin, Ching-Hung, Lu, Yen-Shen, Wo, Andrew M.
Publicado 2020

Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis

por Peng, Shang‐Hsuan, Lin, Ching‐Hung, Chen, I‐Chun, Shen, Ying‐Chun, Chang, Dwan‐Ying, Chen, Tom Wei‐Wu, Huang, Shu‐Min, Hu, Fu‐Chang, Lu, Yen‐Shen
Publicado 2023

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

por Chen, I-Chun, Hsiao, Li-Ping, Huang, I-Wen, Yu, Huei-Chieh, Yeh, Ling-Chun, Lin, Ching-Hung, Wei-Wu Chen, Tom, Cheng, Ann-Lii, Lu, Yen-Shen
Publicado 2017

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

por Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce
Publicado 2021

Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma

por Lien, Huang-Chun, Hsu, Chia-Lang, Lu, Yen-Shen, Chen, Tom Wei-Wu, Chen, I.-Chun, Li, Yu-Chia, Huang, Chiun-Sheng, Cheng, Ann-Lii, Lin, Ching-Hung
Publicado 2023

Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices

por Ma, Wei-Li, Chang, Dwan-Ying, Lin, Ching-Hung, Liu, Kao-Lang, Liang, Po-Chin, Lien, Huang-Chun, Hu, Chan-Chuan, Huang, Ling-Yun, Yeh, Yi-Chun, Lu, Yen-Shen
Publicado 2022